2022年12月10日,

Herbolea生物技術和Iberfar宣布戰略夥伴關係和商業關係SESTO佛羅倫薩,意大利- 12月10日2022 - (Newswire.com) Iberfar工業Farmaceutica年代。(“Iberfar”),一個葡萄牙製藥集團操作裏斯本附近的一個最先進的生產設備,和Herbolea生物技術SpA (“Herbolea”),一個意大利的生物技術公司,許可專有技術無溶劑萃取的植物,很高興宣布簽署許可協議授予Iberfar權利利用Herbolea的提取和純化技術在葡萄牙。作為協議的一部分,Herbolea提交提供良好生產規範(GMP) Iberfar兼容的設備,有能力每年超過400.000公斤的新鮮生物過程。簽署本協議,雙方共同開發目標在歐洲最大的不溶解的生產中心,利用最有效的和有競爭力的提取技術,最高質量的生物量(剛處理,從不幹或冷凍),和一個設施已經授權生產一係列CBD和THC產品(包括麻醉藥品許可協議)。在這個新的夥伴關係Herbolea將提供三個核心技術:Bio-Herbolysis™——專利和環保技術,可以提取大麻植物的完整phyto-complex成脂質基礎從濕材料。這部小說過程可以直接處理新鮮植物材料,不需要幹燥;節省成本、時間和空間。高溫不利用過程中,因此,萜烯完全保留。Hydrocan™是Herbolea不溶解的和環保的技術,有選擇地集中大麻類超過90%截至THC沒有越過法律效力,同時0.2%的閾值在任何一步的過程。Distillac™淨化協議允許提取揮發性化合物(大麻素酸萜烯)的Bio-Herbolysis脂質提取以極高的效率(98%)。 Contrary to popular belief, the team at Herbolea has found that by means of specific processing conditions, it is possible to concentrate cannabinoid acids out of the lipid extract without incurring decarboxylation, therefore preserving the original plant fingerprint unaltered. "This agreement is an important milestone for Herbolea. We are proud and delighted that a leading European pharmaceutical company with more than a hundred years of history has chosen our platform for cannabis extraction," said Marco Merciai, CEO at Herbolea Biotech. "This is yet another sign that the world is moving in the direction of sustainable manufacturing. By signing this agreement Herbolea confirms its leadership in the European cannabis extraction landscape." ABOUT HERBOLEA BIOTECH SpA Herbolea is a biotech company envisioning the use of innovative, green technologies to obtain safe, high-quality and low-cost natural products. Herbolea's patented Bio-Refining Platform generates unique products from highly therapeutic potential botanicals in a safe, environmentally friendly, and cost-competitive way. The company has signed licensing agreements with pharma companies in Canada, Colombia, Germany, Italy, Thailand, U.S. and Portugal. Contact info@herbolea.com to learn more. Contact Information: